Sjögren’s syndrome (pronounced SHOW-grenz) is a chronic, see it here systemic autoimmune disease characterized primarily by progressive lymphocytic infiltration and destruction of the exocrine glands. While it can affect any organ system, its hallmark manifestations involve the lacrimal and salivary glands, leading to severe mucosal dryness—classically presented as keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth).
Sjögren’s syndrome affects approximately $0.1\text{–}0.6%$ of the general population, exhibiting a striking female-to-male predominance of roughly 9:1, with diagnosis most commonly occurring in the fourth to sixth decades of life. The condition occurs either as Primary Sjögren’s Syndrome (pSS), developing independently without another underlying systemic disease, or as Secondary Sjögren’s Syndrome, presenting in association with other autoimmune conditions such as Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), or Systemic Sclerosis.
Immunopathogenesis: Focal Lymphocytic Infiltration and B-Cell Hyperactivity
The underlying pathology of Sjögren’s syndrome combines epithelial dysfunction, autoantibody production, and chronic focal inflammatory destruction.
[ Genetic Susceptibility (HLA-DR/DQ) & Environmental Triggers (Viral) ]
│
▼
[ Epithelial Cell Activation ("Autoimmune Epithelitis") ]
│
┌────────────────────────────────────────┴────────────────────────────────────────┐
▼ ▼
[ Type I Interferon Pathway Activation ] [ B-Cell Hyperactivity & Autoantibodies ]
• Infiltration of $CD4^+$ T-cells & dendritic cells • Production of anti-Ro/SSA & anti-La/SSB
• Secretion of pro-inflammatory cytokines (BlyS/BAFF) • Polyclonal hypergammaglobulinemia
│ │
└────────────────────────────────────────┬────────────────────────────────────────┘
│
▼
[ Progressive Exocrine Gland Atrophy & Fibrosis ]
│
▼
[ Mucosal Sicca Symptoms & Risk of MALT Lymphoma ]
1. Autoimmune Epithelitis
The salivary and lacrimal glandular epithelial cells (ductal and acinar cells) play an active role in driving disease onset. Triggered by environmental factors (such as latent viral infections) in genetically susceptible individuals, these epithelial cells express high levels of MHC Class II molecules and costimulatory signals. They secrete chemokines that recruit immune cells into glandular tissue—a process known as autoimmune epithelitis.
2. Focal Lymphocytic Infiltrates and B-Cell Hyperactivity
- T-Cell Driven Destruction: Infiltrating $CD4^+$ T-helper cells ($\text{Th1}$ and $\text{Th17}$ subsets) secrete pro-inflammatory cytokines, inducing apoptosis of acinar epithelial cells and progressive glandular atrophy.
- B-Cell Activation: Plasmacytoid dendritic cells release high levels of Type I Interferons, upregulating B-lymphocyte stimulator (BLyS / BAFF). This drives B-cell hyperactivation, leading to polyclonal hypergammaglobulinemia and the production of disease-defining autoantibodies:
- Anti-Ro/SSA (specifically 52 kDa and 60 kDa antigens) and Anti-La/SSB antibodies.
- Rheumatoid Factor (RF) and Antinuclear Antibodies (ANA).
Clinical Spectrum: From Glandular Dryness to Systemic Disease
Although mucosal dryness dominates early presentation, Sjögren’s syndrome is a systemic disorder capable of widespread extraglandular complications.
[ Clinical Features of Sjögren's ]
│
┌──────────────────────────────────────────┴──────────────────────────────────────────┐
▼ ▼
[ Exocrine / Sicca Manifestations ] [ Extraglandular / Systemic Features ]
• Keratoconjunctivitis sicca (grittiness, burning) • Inflammatory arthralgias & symmetric synovitis
• Xerostomia (dysphagia, dental caries, oral candidiasis) • Cutaneous vasculitis (palpable purpura)
• Bilateral parotid gland enlargement • Interstitial lung disease & peripheral neuropathy
1. Exocrine Glandular (Sicca) Symptoms
- Ocular (Dry Eyes): Patients report persistent burning, Source grittiness, or a “foreign body sensation” in the eyes. Reduced tear production damages the corneal and conjunctival epithelium, risking corneal ulceration and infection.
- Oral (Dry Mouth): Severe reduction in salivary flow leads to difficulty swallowing dry food without liquids, altered taste, persistent oral burning, rampant dental caries (particularly along cervical tooth margins), and recurrent oral Candida infections.
- Glandular Enlargement: Recurrent, painless or tender bilateral enlargement of the parotid or submandibular glands occurs in up to 50% of patients.
2. Extraglandular (Systemic) Manifestations
Extraglandular features affect approximately one-third of patients with primary Sjögren’s syndrome:
- Musculoskeletal: Non-erosive inflammatory polyarthralgias or mild symmetric synovitis affecting small joints.
- Dermatologic: Raynaud’s phenomenon, severe skin dryness (xerosis), and cutaneous leukocytoclastic vasculitis manifesting as palpable purpura on the lower extremities.
- Pulmonary & Renal: Interstitial Lung Disease (ILD) and lymphocytic interstitial nephritis or distal Renal Tubular Acidosis (RTA Type 1).
- Neurological: Peripheral neuropathies, including sensory ganglioneuropathy and painful small-fiber neuropathy.
3. Malignant Lymphoma Risk
Patients with primary Sjögren’s syndrome face a 15- to 20-fold increased risk of developing Non-Hodgkin Lymphoma, primarily low-grade Mucosa-Associated Lymphoid Tissue (MALT) lymphoma of the salivary glands. Clinical red flags include persistent unilateral parotid enlargement, monoclonal gammopathy, persistent leukopenia, and low serum complement ($C_4$) levels.
Diagnostic Workup and Objective Testing
Diagnosing Sjögren’s syndrome requires integrating clinical symptoms, objective measures of ocular and oral dryness, serological testing, and histological confirmation:
| Diagnostic Domain | Objective Testing Modalities | Diagnostic Cut-Off Criteria |
|---|---|---|
| Ocular Dryness Evaluation | Schirmer’s Test: Measures tear production using filter paper placed in the lower eyelid. |
Ocular Surface Staining: Evaluates corneal and conjunctival damage via lissamine green or fluorescein dye. | Schirmer’s test $\le 5\text{ mm}$ in 5 minutes.
Ocular Surface Staining score $\ge 5$. |
| Oral Secretion Evaluation | Unstimulated Whole Salivary Flow Rate: Measures total passive saliva collection over time. | Unstimulated salivary flow $\le 0.1\text{ mL/minute}$. |
| Serological Testing | ELISA / Multiplex Autoantibody Screening: Tests for circulating autoimmune antibodies. | High positivity for Anti-Ro/SSA antibodies. |
| Histological Evaluation | Minor Salivary Gland Biopsy: Surgical harvest of lower lip labial salivary glands to assess lymphocytic foci. | Focus Score $\ge 1$: Defined as $\ge 50$ lymphocytes per $4\text{ mm}^2$ of glandular tissue. |
Diagnosis is guided by the 2016 ACR/EULAR Classification Criteria, requiring a total score of $\ge 4$ points across these weighted objective domains.
Therapeutic Management: Symptom Relief and Systemic Control
Management combines topical secretagogues and tear replacements for sicca symptoms with systemic immunosuppression for extraglandular disease.
[ Primary Symptomatic Evaluation ]
│
▼
[ Localized Sicca Management ] ──► (Preservative-free tears, Pilocarpine / Cevimeline)
│
▼
[ Moderate Systemic Involvement (Arthralgia / Fatigue) ] ──► (Hydroxychloroquine [HCQ])
│
▼
[ Severe Extraglandular Organ Manifestations ] ──► (Systemic Corticosteroids + Immunosuppressants / Rituximab)
1. Management of Sicca Symptoms
- Ocular Therapy: Preservative-free artificial tears, nocturnal lubricating ointments, topical anti-inflammatory drops (e.g., cyclosporine or lifitegrast), and surgical punctal occlusion to retain natural tear film.
- Oral Therapy: Frequent oral hydration, saliva substitutes, strict oral hygiene, topical fluoride applications, and oral muscarinic receptor agonists (Pilocarpine or Cevimeline) to stimulate residual functional salivary tissue.
2. Systemic Pharmacotherapy
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Hydroxychloroquine (HCQ) is commonly prescribed to manage systemic fatigue, arthralgias, and hypergammaglobulinemia.
- Immunosuppression for Severe Systemic Disease: Systemic corticosteroids combined with conventional DMARDs (e.g., Azathioprine, Mycophenolate mofetil) or B-cell depleting therapies (Rituximab) are utilized for severe extraglandular involvement, such as vasculitis, severe ILD, or glomerulonephritis.
Conclusion
Sjögren’s syndrome is an autoimmune disorder characterized by exocrine dysfunction, mucosal dryness, and potential extraglandular organ complications. By utilizing objective diagnostic criteria—including anti-Ro/SSA serology, Schirmer’s testing, and minor salivary gland biopsies—clinicians can establish an accurate diagnosis. Combining targeted local secretagogue therapies with systemic immunosuppressive monitoring allows care teams to relieve sicca distress, visit this page manage systemic complications, and monitor for lymphoma risk.